U.S. Markets closed

A Performance Overview of Merck’s Cardiovascular Segment

Daniel Collins
A Performance Overview of Merck’s Cardiovascular Segment

Merck & Co.’s (MRK) Zetia generated revenues of $165 million in the third quarter, reflecting a ~48% YoY (year-over-year) decline and a ~27% sequential decline. Zetia reported net revenues of $696 million in the first nine months of the year compared to $1 billion in the same period of 2017, reflecting a ~32% YoY decline.